As part of its annual media conference in Bern on Wednesday, Curafutura criticizes that 7 out of 20 drugs are based on a non-transparent price model, “we only know the window price”. According to the analysis presented, the twenty best-selling drugs on the federal specialty list generated sales of approximately 1.7 billion francs from October 2021 to September 2022.
Within a year, these twenty drugs increased 13 percent more than other drugs on the specialty list reimbursed by health insurers. Second, it only increased by five percent in price.
In light of this development, Curafutura finds it questionable whether the Federal Council wants to expand its price models further. The association complains that a quick and effective solution is available with the so-called budget impact model. In June 2020, the Federal Parliament accepted the corresponding proposal from the liberal Uri Council of States Josef Dittli.
Health insurers CSS, Helsana, Sanitas and KPT are owned by Curafutura.
(SDA)
Source :Blick
I’m Tim David and I work as an author for 24 Instant News, covering the Market section. With a Bachelor’s Degree in Journalism, my mission is to provide accurate, timely and insightful news coverage that helps our readers stay informed about the latest trends in the market. My writing style is focused on making complex economic topics easy to understand for everyone.
